Smoking cessation drug pipelines shift to novel mechanisms and alkaloids
Global smoking cessation drug pipelines face a critical therapeutic bottleneck as developers pursue novel mechanisms to bypass the safety and manufacturing hurdles that stalled standard treatments over the past two decades. With tobacco-related deaths exceeding 8 million annually worldwide, researchers are shifting focus toward plant-derived alkaloids, multi-receptor modulators, and incretin therapies to address both nicotine … Read more